Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03736967
Recruitment Status : Completed
First Posted : November 9, 2018
Last Update Posted : August 6, 2020
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD).

Secondary Objectives are to:

  • Evaluate the efficacy of REGN3500 in combination with dupilumab compared with placebo treatment in adult patients with moderate-to-severe AD
  • Assess the safety, tolerability, and immunogenicity of subcutaneous (SC) doses of REGN3500 monotherapy and REGN3500 in combination with dupilumab in adult patients with moderate-to-severe AD
  • Evaluate the Pharmacokinetic (PK) of REGN3500 monotherapy and REGN3500 in combination with dupilumab in adult patients with moderate-to-severe AD

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: REGN3500 Drug: Dupilumab Drug: REGN3500 + Dupilumab Combo Drug: Placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 206 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Actual Study Start Date : November 12, 2018
Actual Primary Completion Date : March 13, 2020
Actual Study Completion Date : July 28, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema
Drug Information available for: Dupilumab

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: REGN3500 Drug: REGN3500
Administered subcutaneous (SC) every 2 weeks (q2w)
Experimental: Dupilumab Drug: Dupilumab
Administered SC q2w
Other Names:
  • REGN668
  • Dupixent
Experimental: Combo Drug: REGN3500 + Dupilumab Combo
Administered SC q2w
Other Names:
  • REGN668
  • Dupixent
Experimental: Placebo Drug: REGN3500
Administered subcutaneous (SC) every 2 weeks (q2w)

Drug: Dupilumab
Administered SC q2w
Other Names:
  • REGN668
  • Dupixent

Drug: Placebo
Administered SC q2w


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percent change in Eczema Area and Severity Index (EASI) score [ Time Frame: Baseline to week 16 ]
    EASI is a composite index with scores ranging from 0 to 72


Secondary Outcome Measures :
  1. Proportion of patients achieving EASI-50 [ Time Frame: Week 16 ]
    (≥50% improvement from baseline)

  2. Proportion of patients achieving EASI-75 [ Time Frame: Week 16 ]
    (≥75% improvement from baseline)

  3. Proportion of patients achieving EASI-90 [ Time Frame: Week 16 ]
    (≥90% improvement from baseline)

  4. Absolute change in EASI score [ Time Frame: From baseline to week 16 ]
    EASI is a composite index with scores ranging from 0 to 72

  5. Proportion of patients with an Investigator's Global Assessment (IGA) score of 0 or 1 (on a 5-point scale) [ Time Frame: Week 16 ]
  6. Proportion of patients with an IGA score reduction of ≥2 points [ Time Frame: Week 16 ]
  7. Absolute change in weekly average of daily peak Pruritus Numerical Rating Scale (NRS) [ Time Frame: Baseline to Week 16 ]
    Range of 0 (No itch) to 10 (Worst imaginable itch)

  8. Percent change in weekly average of daily peak Pruritus Numerical Rating Scale (NRS) [ Time Frame: Baseline to Week 16 ]
  9. Proportion of patients with improvement (reduction) of weekly average of daily peak Pruritus NRS ≥4 [ Time Frame: Week 16 ]
  10. Time to onset of effect on pruritus [ Time Frame: Baseline to Week 16 ]
    ≥4-point reduction of weekly average of daily peak Pruritus NRS

  11. Percent change in SCORing Atopic Dermatitis (SCORAD) [ Time Frame: Baseline to Week 16 ]
  12. Change in percent body surface area (BSA) of AD involvement [ Time Frame: Baseline to Week 16 ]
  13. Incidence of treatment-emergent adverse events (TEAEs) from baseline through end of week 16 [ Time Frame: Week 16 ]
  14. Incidence of treatment-emergent SAEs from baseline through end of treatment [ Time Frame: Week 16 ]
  15. Incidence of treatment-emergent adverse events of special interest (AESIs) from baseline through end of treatment [ Time Frame: Week 16 ]
  16. Incidence of TEAEs from baseline through end of study [ Time Frame: Week 36 ]
  17. Incidence of treatment-emergent SAEs from baseline through end of study [ Time Frame: Week 36 ]
  18. Incidence of treatment-emergent AESIs from baseline through end of study [ Time Frame: Week 36 ]
  19. Serum REGN 3500 concentration [ Time Frame: Up to Week 36 ]
  20. Serum dupilumab concentration [ Time Frame: Up to Week 36 ]
  21. Incidence of treatment-emergent anti-drug antibodies to REGN3500 [ Time Frame: Up to Week 36 ]
  22. Incidence of treatment-emergent anti-drug antibodies to dupilumab [ Time Frame: Up to Week 36 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Chronic AD, according to American Academy of Dermatology Consensus Criteria (Eichenfield, 2014), that has been present for at least 3 years before the screening visit
  2. Eczema Area and Severity Index (EASI) score ≥16 at the screening and baseline visits
  3. ≥10% Body surface area (BSA) of AD involvement at the screening and baseline visits
  4. Documented recent history (within 6 months before the screening visit) of inadequate response to topical AD medication(s) or for whom topical treatments are medically inadvisable

Key Exclusion Criteria:

  1. Prior participation in an anti-Interleukin (IL)-33 class antibody (including but not limited to REGN3500) or anti-IL-4Rα class antibody (including but not limited to dupilumab) clinical study; past treatment with or current treatment with dupilumab or another anti-IL-4Rα treatment
  2. Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit
  3. Known or suspected history of immunosuppression, including history of invasive opportunistic infections (eg, tuberculosis (TB), histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution: or unusually frequent, recurrent, or prolonged infections, per investigator judgment
  4. History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening
  5. Positive with hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus antibody (HCV Ab) at the screening visit
  6. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study

Note: Other protocol defined Inclusion/Exclusion Criteria apply

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03736967


Locations
Show Show 66 study locations
Sponsors and Collaborators
Regeneron Pharmaceuticals
Sanofi
Investigators
Layout table for investigator information
Study Director: Clinical Trial Management Regeneron Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03736967    
Other Study ID Numbers: R3500-AD-1798
2018-001543-30 ( EudraCT Number )
First Posted: November 9, 2018    Key Record Dates
Last Update Posted: August 6, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Regeneron Pharmaceuticals:
Moderate
Severe
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
 Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs